Preclinical studies have shown AFP-mRNA vaccines can elicit CTL responses, providing protection against AFP-expressing HCC tumors, while others have reported AFP vaccination may result in M2 macrophage polarization (201, 202). The gene discussed is AFP; the disease is hepatocellular carcinoma.